000			03635nam a22004335i 4500
988			_aSpringer_BiomedLife_2019
999			_c116813 _d116813 _x1
001			116813
003			ES-MaUEC
005			20230104140207.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			190715s2019 gw | s |||| 0|eng d
020			_a9783030214777
024	7		_a10.1007/978-3-030-21477-7 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRM301.63 _b2019 EB
245	0	0	_aCurrent Applications for Overcoming Resistance to Targeted Therapies _cedited by Myron R. Szewczuk, Bessi Qorri, Manpreet Sambi.
250			_a1st ed. 2019.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2019
300			_a1 recurso en línea (XVIII, 320 páginas) _b31 ilustraciones, 29 ilustraciones
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF _2rda
490	0		_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501 _v20
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aIntroduction to the Acquisition of Resistance to Targeted Therapy -- Targeting the Tumor Microenvironment to Overcome Resistance to Targeted Therapy -- Current Challenges and Applications of Oncolytic Viruses in Overcoming Resistance to Therapies in Cancer -- Novel Methods to Overcome Acquired Resistance to Immunotherapy -- Therapies to Overcome Multidrug-Resistant Receptors -- Overcoming Resistance to PARP Inhibition -- Novel Methods of Overcoming HER2 Therapy Resistance in Breast Cancer -- Emerging Novel Therapies for Overcoming Resistance to Targeted Therapies -- Targeting Epigenetic Regulators in Cancer to Overcome Resistance to Targeted Therapy -- Nanomedicine and Drug Delivery Systems in Overcoming Resistance to Targeted Therapy -- Index.
520	3		_aTargeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.
650		7	_2embne _9395061 _aMedicamentos _xDiseño
700	1		_aSzewczuk, Myron R _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aQorri, Bessi _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aSambi, Manpreet _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030214760
776	0	8	_iPrinted edition: _z9783030214784
776	0	8	_iPrinted edition: _z9783030214791
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-21477-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _cm _dz _feng _ggw _h0 _b01/2020 _ek _zSI